Navigation Links
Mylan's Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
Date:6/1/2009

PITTSBURGH, June 1 /PRNewswire-FirstCall/ --

WHAT: Mylan Inc. (Nasdaq: MYL) has accepted an invitation to testify before the U.S. House of Representatives Judiciary Subcommittee on Courts and Competition Policy at its upcoming hearing: "Pay to Delay: Are Patent Settlements That Delay Generic Drug Market Entry Anticompetitive?" Mylan was invited to testify by Committee on the Judiciary Chairman Rep. John Conyers Jr. (D-MI).

WHO: Mylan Chief Operating Officer Heather Bresch will testify on behalf of the company. As part of Mylan's testimony, Bresch will address impediments that unfairly delay consumer access to affordable generic pharmaceuticals, including authorized generics during the 180-day exclusivity period.

WHEN: Wednesday, June 3, 2009 at 10:00 a.m.

WHERE: 2141 Rayburn House Office Building, Washington, D.C.

WEBCAST: www.judiciary.house.gov/hearings/calendar.html

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Mediware Names Thomas K. Mann Chief Executive Officer
4. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
5. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
6. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
7. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
10. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
11. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... downstream client survey, marketing channels, industry development trend ... of the industry, including spices definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:3/4/2015)... GA (PRWEB) March 04, 2015 ... advanced microfiber technology and their first compression therapy collection ... success of this collection, SIGVARIS USA is proud to ... MIDTOWN MICROFIBER product line. , Constructed from a unique, ... all-day comfort in mind. These socks and thigh-highs offer ...
(Date:3/4/2015)... In a small ceremony with 20 attendees ... new facility in New Port Richey on February 24, 2015 ... will allow the Florida drug detox facility to ... epidemic through treatment and education. “Due to our unique medical-detox ... United States, we made the decision that expanding our facility ...
(Date:3/4/2015)... Today Visiopharm announces that Patrik Dahlén, previously the ... Visiopharm Board of Directors as Chairman. Mr. ... positioned to become the fastest growing software company, specializing ... , "Over the last several years, Visiopharm ... ONCOtopix™ Dx, a complete quantitative digital pathology solution for ...
(Date:3/4/2015)... A new dieting routine, called the ... of extending life. Studies conducted by the ... routine can help extend life by increasing anti-oxidant production. ... term benefits, many suffering from obesity are already experiencing ... necessary. As an alternative to the new Feast and ...
Breaking Medicine News(10 mins):Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
... it is observed that women are more likely to experience ... research shows that women are less likely to get prompt ... issue, for 'clotbusting' drugs must be given very rapidly if ... now suggest why there could be a delay in diagnosing ...
... at National Jewish Medical and Research Center report in ... atopic dermatitis, also known as eczema, are susceptible to ... produce effective amounts of two antimicrobial peptides. The findings ... and suggest that a medication containing or inducing the ...
... from a study of a new drug for children ... intravenously every three weeks, was found to be partially ... one of a group of drugs called chloroethylnitrosoureas. They ... shown to help shrink solid tumors, including cancerous brain ...
... showing that calcium channel blockers are more effective at ... group of 1,800 patients were assigned to either lacidipine,// ... are used to treat high blood pressure, but act ... at which calcium flows into cells and so interferes ...
... it is observed that a surgically implanted shunt could help ... draining cerebrospinal fluid. This type of shunting was first used ... used// when there seemed to be a high incidence of ... type of shunting on patients with abnormal amounts of spinal ...
... of the antioxidant vitamin E may assist in reducing ... Health Study and the Health Professionals Follow-Up Study', presented by ... Parkinson's disease. The participants have been followed up for several ... ,Those with a high intake of vitamin E ...
Cached Medicine News:Health News:Eczema patients lack natural antibiotic in skin 2
(Date:3/4/2015)... March 4, 2015 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... will participate in the upcoming 27 th Annual ... Dana Point, CA.  Dr. Michael ... Oramed, will present a corporate overview on March 10, ...
(Date:3/4/2015)... Mallinckrodt plc (NYSE: MNK ), a ... Global Healthcare Conference at the Loews Miami Hotel in ... 11, 2015. Mark Trudeau, President and Chief Executive Officer of ... to begin at 10:45 a.m. Eastern. Individuals ... webcast information on Mallinckrodt,s Investor Relations website ...
(Date:3/4/2015)... NEWARK, N.J. , March 4, 2015 /PRNewswire/ ... biopharmaceutical company developing innovative medicines for serious women,s ... 1 clinical program demonstrating that its lead product ... had predictable pharmacokinetics (PK), and that contraceptive efficacy ... by SYM-1219 administration. These results will ...
Breaking Medicine Technology:Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3Mallinckrodt to Present at Barclays Conference March 11 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 2Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 3Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 4Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 5
... MedShape Solutions, Inc., the industry leader in innovative ... developed new, larger sizes of its ExoShape CL, ... simplifies and improves soft tissue graft fixation during ... comes after MedShape received the U.S. Food and ...
... Neuralstem, Inc. (NYSE Amex: CUR ) announced that ... the ongoing Phase Ia trial to test the safety of ... testing the drug in healthy volunteers for safety and tolerability. ... that stimulates new neuron growth in the hippocampus, an area ...
Cached Medicine Technology:MedShape Solutions, Inc. Announces Extension of ExoShape™ Product Line in Response to Surgeon Demand 2Neuralstem Updates NSI-189 Major Depression Trial 2Neuralstem Updates NSI-189 Major Depression Trial 3
... the High Performance line, Zebra's 110XiIIIPlus is a ... hardworking printer is the one to call on ... available with either 4.09 inch (104 mm) or ... that best meets your needs, either 200, 300, ...
... tested XiIIIPlus platform, the R110Xifor four-inch ... on-demand printing flexibility in tag placement ... as XML for seamless integration into ... positioning, multiple power levels, statistics tracking, ...
... prints labels up to 8.5 ... It is ideal for wide ... chemical drum labels, primary metal ... banner-sized labels and pallet and ...
... CareChek Tx, which has received ... device for blood transfusions, allows ... patient to the unit of ... administering a transfusion.The system can ...
Medicine Products: